Академический Документы
Профессиональный Документы
Культура Документы
P R E S E N T E D B Y:
D A N T RA N
A M B U L AT O RY C A S E P R E S E N TAT I O N
OBJECTIVES
By the end of this presentation, you should be able
to:
SETTING
MTM and Medication Review Consult
New Patient to Franciscan Clinic
Cold Visit:
Reported chronic renal failure by referring physician.
No Prior Drug History, and no med list
No access to patient lab results
OVERVIEW OF CASE
MM is a 90 yr old caucasian female with recent
hospital discharge following a fall incident.
Clinical S/Sx:
Remarkably able-bodied,
appears obese, reports
feeling healthy, complains
about pain and
tenderness in great toe
SH:
Lives with husband in nonsmoking home.
Frequently gardens in backyard.
Denies alcohol use.
PMH:
Chronic Conditions:
Gout
Edema
Diabetes
Hyperlipidemia
Glaucoma
hypothyroidism
MEDICATION THERAPY
Indication
Drug
Gout
Allopurinol
Hypertension
Dose
Route
Duration/Frequency
300 mg
1 tablet
Po
Daily
Furosemide
20 mg
2 tablets
Po
Daily
Hyperlipidemi
a
Thyroid
Simvastatin
40 mg
1 tablet
Po
At bedtime
125 mcg
1 tablet
Po
Daily
Diabetes
Glipizide XL
2.5 mg
1 tablet
Po
Daily
Metformin
500 mg
1 tablet
Po
Twice a day
Glaucoma
PE
Prophylaxis
Pain
Levothyroxine
Strength
Timolol Maleate
0.5%
1 drop
Travoprost
Warfarin Sodium
0.004%
1 drop
3 mg
1 tablet
Po
Daily on Su/Tu/Th/Sa
Warfarin Sodium
2 mg
1 tablet
Po
Daily on Mon/Wed/Fri
25 mg
1 tablet
Po
1 capsule
Po
Tramadol
Acetaminophen
500 mg
Evaluation
Presence of
inflammation in the
great toe indicative
of podagra
MM is taking
allopurinol 300 mg
for her gout
GOUT: ETIOLOGY 1
Acute arthritis associated with monosodium urate
crystals in synovial fluid
Uric acid is a byproduct of xanthine oxidase in purine
metabolism
DIAGNOSIS OF GOUT
Dx: 1977 ARA Criteria (any 6 of the following)
Etiology-related
1. Hyperuricemia
2. Monosodium urate microcrystals in joint
fluid during attack
1.
2.
3.
4.
Unknown
1.
2.
3.
4.
Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Y T-F. Preliminary criteria for the
classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
1.
2.
Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic
therapeutic approaches to hyperuricemia. Arthritis care & research 64.10 (2012): 1431-1446.
Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute
gouty arthritis. Arthritis care & research 64.10 (2012): 1447-1461.
ACUTE GOUT 1
Goal: Stop the acute gout attack!
1st Line: Non-Pharmacologic
CHRONIC GOUT
2 or more attacks per year = Chronic Gout
Therapy
Uricosuric Drug vs. Xanthine
.AllopurinolOxidase Inhibitor
Probenecid
ALTERNATIVE TREATMENT?
Uloric (febuxostat) 4
Xanthine Oxidase inhibitor
Recommended starting dose: Uloric 40 mg once daily
ALTERNATIVE TREATMENT?
Krystexxa (pegloticase) 5
PEGylated enzyme specific for uric acid
Administered as IV push or bolus. Requires discontinuation of oral
urate-lowering agents before starting therapy.
No dose adjustment for renal or hepatic impairment
CARE PLAN
Monitor: Inflammation, worsening of symptoms
of hyperuricemia including joint pain or podagra,
renal function.
Efficacy: reduction/resolution of acute gout symptoms.
Toxicity: monitor for worsening symptoms, hyperuricemia,
reduction in renal function (SCr, CrCl
QUIZ TIME!
MMs doctor asks you for an alternative drug
treatment option instead of allopurinol for MMs
chronic gout due to her severe renal insufficiency.
What other drug can you suggest?
1.
2.
3.
4.
Probenecid
Uloric
Zyloprim
There are no alternatives.
A. Colchicine
B. Non-pharmacologic
C. NSAIDS
D. Steroids
Order: ____ , _____ , _____ , _____
REFERENCES
1.
Pittman JR, Bross MH. Diagnosis and Management of Gout. Am Fam Physician 1999
Apr 1; 59(7):1799-1806
2.
Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Y T-F. Preliminary criteria for
the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895900.
3.
4.
Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2012.
5.
6.
7.
Krystexxa [package insert]. East Brunswick, NJ: Savient Pharmaceuticals, Inc.; 2010.